• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244

Introduction to 3,6-Difluoro-2-iodotoluene (CAS No: 1208077-96-6)

3,6-Difluoro-2-iodotoluene, identified by its Chemical Abstracts Service (CAS) number 1208077-96-6, is a fluorinated aromatic compound that has garnered significant attention in the field of organic synthesis and pharmaceutical research. This compound serves as a versatile intermediate in the development of various chemical entities, particularly in the synthesis of bioactive molecules. The presence of both iodine and fluorine substituents makes it a valuable building block for constructing more complex structures, enabling access to novel pharmacophores with enhanced biological activity.

The structural features of 3,6-Difluoro-2-iodotoluene include a benzene ring substituted with two fluorine atoms at the 3 and 6 positions, and an iodine atom at the 2 position. This arrangement imparts unique electronic and steric properties to the molecule, which are highly useful in medicinal chemistry. The fluorine atoms can influence the metabolic stability and binding affinity of drug candidates, while the iodine atom provides a handle for further functionalization via cross-coupling reactions such as Suzuki-Miyaura or Stille couplings.

In recent years, there has been a growing interest in fluorinated aromatic compounds due to their prevalence in approved drugs and their potential to improve pharmacokinetic profiles. For instance, fluorine atoms can enhance lipophilicity, reduce metabolic clearance, and increase binding interactions with biological targets. The compound 3,6-Difluoro-2-iodotoluene exemplifies this trend, as it can be used to generate derivatives with improved drug-like properties.

One of the most compelling applications of 3,6-Difluoro-2-iodotoluene is in the synthesis of small-molecule inhibitors targeting protein-protein interactions (PPIs). PPIs are critical therapeutic targets but have proven challenging to modulate due to their lack of well-defined binding pockets. Fluorinated aromatic compounds have shown promise in disrupting these interactions by altering hydrophobicity and electronic distributions. Research has demonstrated that derivatives of 3,6-Difluoro-2-iodotoluene can serve as scaffolds for developing potent PPI modulators. For example, recent studies have highlighted its utility in creating inhibitors of kinases and other enzymes involved in cancer pathways.

The role of 3,6-Difluoro-2-iodotoluene extends beyond kinase inhibition. It has been employed in the synthesis of compounds targeting neurological disorders such as Alzheimer's disease and Parkinson's disease. The ability to introduce fluorine atoms at specific positions allows for fine-tuning of molecular properties that can enhance blood-brain barrier penetration and reduce off-target effects. Furthermore, the iodine moiety enables further derivatization through transition-metal-catalyzed reactions, providing access to a diverse array of analogs for structure-activity relationship (SAR) studies.

Advances in synthetic methodologies have further expanded the utility of 3,6-Difluoro-2-iodotoluene. Techniques such as palladium-catalyzed cross-coupling reactions have made it possible to efficiently incorporate various functional groups into the molecule. This flexibility has allowed researchers to generate libraries of compounds for high-throughput screening (HTS), accelerating the discovery process. Additionally, computational methods such as molecular modeling and quantum mechanical calculations are being increasingly used to predict the properties of derivatives before they are synthesized, thereby optimizing lead optimization efforts.

The pharmaceutical industry has recognized the importance of intermediates like 3,6-Difluoro-2-iodotoluene in drug discovery pipelines. Companies are investing in high-quality suppliers who can provide pure and consistent batches of these compounds. The demand for specialized intermediates is driven by the need for innovative therapies that address unmet medical needs. As a result, research into new synthetic routes and applications for 3,6-Difluoro-2-iodotoluene continues to thrive.

In conclusion,3,6-Difluoro-2-iodotoluene (CAS No: 1208077-96-6) is a multifaceted compound with significant potential in medicinal chemistry and drug development. Its unique structural features enable its use as a key intermediate in synthesizing bioactive molecules targeting various diseases. The ongoing research into its applications underscores its importance as a tool for innovation in chemical biology and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)